The World Health Organization has issued an emergency use listing (EUL) for Nuvaxovid, following its assessment and approval by the European Medicines Agency (EMA).
WHO disclosed this in a statement made available to the press on Tuesday, December 21, 2021.
TheFactNigeria observed that the need for more vaccines became necessary as deadlier variants of the covid-19 virus were being discovered.
Nuvaxovidis the 10th covid-19 vaccine being listed for emergency use, it was developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI).
Covovax™ vaccine which received WHO emergency use listing on 17 December, 2021 was also produced by Novavax and CEPI. Both vaccines are made using the same technologies, they require two doses and are stable at 2 to 8 °C refrigerated temperatures.
WHO’s Strategic Advisory Group of Experts on Immunization has also issued policy recommendations for Nuvaxovid™ / Covovax™.